Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Lucas Research

Neither a doctor nor a teaching hospital

Research payments

$4,825,615

494 payments

Through program year 2025, Lucas Research is reported as receiving $4,825,615 in research payments, across 494 payments.

By program year

6 rows
Year Kind Amount Payments
2025 Research $44,634 110
2024 Research $525,438 23
2023 Research $683,879 38
2022 Research $1,024,125 16
2021 Research $2,139,730 276
2020 Research $407,809 31

Breakdown

Who paid Research payments · program years 2020–2025
  1. Valneva Austria GmbH $1,832,652 14 payments
  2. Novartis Pharmaceuticals Corporation $1,044,810 13 payments
  3. Roche Diagnostics Operations, Inc. $619,625 25 payments
  4. Roche Molecular Systems, Inc. $500,298 24 payments
  5. Eisai Inc. $230,650 9 payments
  6. Boehringer Ingelheim Pharmaceuticals, Inc. $183,064 19 payments
  7. AbbVie, Inc. $174,534 22 payments
  8. Amgen Inc. $115,352 4 payments
  9. Sanofi US Services Inc. $53,296 81 payments
  10. Boehringer Ingelheim International GmbH $30,196 105 payments
Studies the money was for Research payments · program years 2020–2025
  1. A Multicenter, Randomized, Placebo-Controlled, Double-Blinded Pivotal Study to Evaluate Safety and Immunogenicity of A Live-Atteuated Chikungunya Virus Vaccine Candidate (Vla1553) in Adults Aged 18 Years and Above $1,288,632 12 payments
  2. Immunogenicity and Safety Study of Vla15, A Multivalent Recombinant Ospa Based Vaccine Candidate Against Lyme Borreliosis, in Healthy Adults Aged 18 to 65 Years - A Randomized, Controlled, Observer-Blind Phase 2 Study. $544,020 2 payments
  3. A Randomized, Placebo-Controlled, Participant-And-Investigator- Blinded, Sponsor Open-Label Study to Evaluate the Safety, Tolerability, and Efficacy With Different Dosing Regimens of Subcutaneously Administered Mbl949 in Obese Participants With Or Without $470,551 1 payment
  4. A Randomized, Four-Arm, Placebo-Controlled, Participant, Investigator and Sponsor-Blinded Study Investigating the Safety, Tolerability and Efficacy of Intra-Articular Canakinumab Followed By Intra-Articular Lna043 in Patients With Knee Osteoarthritis $438,600 3 payments
  5. Rd006493 $416,551 17 payments
  6. Rd006318 $370,430 8 payments
  7. Rd006484 $249,195 17 payments
  8. A 52 Week Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Belviq XR??in Conjunction With Lifestyle Modification for Weight Loss in Obese Adolescents, Age 12 to 17 Years $230,650 9 payments
  9. Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (Victorion-2 Prevent) $134,094 6 payments
  10. POCC in NASH $116,892 32 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record